Showing results (121-130 of 272) with videos related to

Sort By:
Pageof 28
BMC Rheumatology|May 22, 2024
Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritisJeffrey A Sparks, Philippe Dieudé, Anna-Maria Hoffmann-Vold, et al.
Annals of the Rheumatic Diseases|June 8, 2018
Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR modelWanlong Wu, Suzana Jordan, Mike Oliver Becker, et al.
Microbial Genomics|August 1, 2023
Results of the 2020 Genomic Proficiency Test for the network of European Union Reference Laboratory for Antimicrobial Resistance assessing whole-genome-sequencing capacitiesThea Kristensen, Lauge Holm Sørensen, Susanne Karlsmose Pedersen, et al.
Annals of the Rheumatic Diseases|October 10, 2020
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)Paolo Spagnolo, Oliver Distler, Christopher J Ryerson, et al.
Rheumatology (Oxford, England)|August 1, 2025
Emphysema elevates the DETECT scores: impact on pulmonary hypertension screening and diagnosis in systemic sclerosisGesa M Sauer, Florian Käs, Carmen-Marina Mihai, et al.
International Journal of Systematic and Evolutionary Microbiology|September 21, 2011
Vibrio caribbeanicus sp. nov., isolated from the marine sponge Scleritoderma cyaneaMaria Hoffmann, Steven R Monday, Marc W Allard, et al.
The Lancet. Rheumatology|January 24, 2024
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trialsAnna-Maria Hoffmann-Vold, Elizabeth R Volkmann, Yannick Allanore, et al.
ERJ Open Research|June 1, 2023
Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptationsSteve Jones, Maxine Flewett, Ron Flewett, et al.
Journal of Scleroderma and Related Disorders|November 15, 2024
A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ studyDinesh Khanna, Jeska de Vries-Bouwstra, Anna-Maria Hoffmann-Vold, et al.
Expert Review of Clinical Immunology|October 20, 2020
The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patientsFrancesco Benvenuti, Elisabetta Zanatta, Jérôme Avouac, et al.
Pageof 28